No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner Pro and Angel Aligner Classic, are bespoke, removable clear aligners designed to gradually guide a patient's teeth into proper alignment over time. Beyond aligner development, the company also operates dental clinics that provide a variety of services, including orthodontics and cosmetic dentistry, and distributes intraoral scanners. Their extensive portfolio of clear aligner brands features Angelalign, Angelalign Pro, Angelalign Kid, and COMFOS. The firm was founded in 2003 and maintains its principal offices in Shanghai, China.
www.angelalign.comNo one on the platform currently holds 6699.HK.
No tracked institution reports a position in 6699.HK as of their last filing.
No one on the platform has traded 6699.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.1% | — | — | — | ||
| Rev. Growth % | 32.2% | 26.0% | ||||
| Profit Margin % | 7.7% | 11.0% | ||||
| Free Cash Flow Margin % | 20.2% | 8.6% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.3B | +36.3% | $1.36 | $1.26–$1.43 | — | 4 |
| 2027 | $3.9B | +20.1% | $2.08 | $1.78–$2.45 | — | 6 |
| 2028 | $4.6B | +16.8% | $3.43 | $2.42–$4.17 | — | 6 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-31 | $0.71 | $1.25 | +77.1% |
| 2026-03-27 | $0.58 | $0.58 | +0.0% |
| 2025-08-25 | $0.66 | $0.66 | +0.0% |
| 2025-03-20 | $0.35 | $0.39 | +9.7% |
| 2024-08-22 | $0.27 | $0.13 | -51.0% |
| 2024-03-19 | $0.12 | $0.13 | +7.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 6699.HKAngelalign Technology Inc. | $88.25 | +0.06% | $15.2B | — |
| 0570.HKChina Traditional Chinese Medicine Holdings Co. Limited | $1.27 | +1.19% | $6.4B | — |
| 1681.HKConsun Pharmaceutical Group Limited | $13.26 | -0.15% | $11.1B | — |
| 1858.HKBeijing Chunlizhengda Medical Instruments Co., Ltd. | $7.72 | -1.47% | $4.6B | — |
| 1931.HKETHK Labs Inc. |
| $0.49 |
| -1.01% |
| $785M |
| — |
| 2157.HKLepu Biopharma Co., Ltd. | $3.98 | +0.00% | $7.2B | — |
| 2186.HKLuye Pharma Group Ltd. | $1.79 | +0.28% | $7.2B | — |
Source: Financial Modeling Prep · peers by sector/industry